Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.

Schöffski, P; Thate, B; Beutel, G; Bolte, O; Otto, D; Hofmann, M; Ganser, A; Jenner, A; Cheverton, P; Wanders, J; Oguma, T; Atsumi, R; Satomi, M

Schöffski, P; Thate, B; Beutel, G; Bolte, O; Otto, D; Hofmann, M; Ganser, A; Jenner, A; Cheverton, P; Wanders, J; Oguma, T; Atsumi, R; Satomi, M.

Affiliation

Schöffski P; Department of Hematology and Oncology, Hannover Medical School, Hannover, Germany. schoeffski.patrick@mh-hannover.de

Ann Oncol ; 15(4): 671-9, 2004 Apr.

Article in En | MEDLINE | ID: mdl-15033678

Subject(s)

Antineoplastic Agents/pharmacokinetics; Neoplasms/drug therapy; Oligopeptides/pharmacokinetics; Adult; Aged; Alopecia/chemically induced; Anorexia/chemically induced; Antineoplastic Agents/adverse effects; Antineoplastic Agents/therapeutic use; Area Under Curve; Constipation/chemically induced; Depsipeptides; Dose-Response Relationship, Drug; Fatigue/chemically induced; Female; Humans; Infusions, Intravenous; Leukopenia/chemically induced; Male; Middle Aged; Nausea/chemically induced; Neoplasms/metabolism; Neutropenia/chemically induced; Oligopeptides/adverse effects; Oligopeptides/chemical synthesis; Oligopeptides/chemistry; Oligopeptides/therapeutic use

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Oligopeptides / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Year: 2004 Document type: Article

Search on Google

XML

PubMed Links